|
|
Home
Search
Study Topics
Glossary
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||||||||||||||||||||||||
| Sponsor: | Assistance Publique - Hôpitaux de Paris |
|---|---|
| Collaborators: |
Groupe Hospitalier Pitie-Salpetriere University Hospital, Bordeaux University Hospital, Limoges Henri Mondor University Hospital University Hospital, Marseille University Hospital, Lyon, France University Hospital, Basel, Switzerland |
| Information provided by: | Assistance Publique - Hôpitaux de Paris |
| ClinicalTrials.gov Identifier: | NCT00259974 |
Purpose
Polyneuropathy associated with anti-MAG monoclonal IgM gammopathy is responsive of mainly a sensory deficit in predominantly males ,aged 40-70 years. Significantly high serum anti-MAG antibodies are linked with demyelinating features of the peripheral nerves.Rituximab, an anti-CD 20 monoclonal antibody is a new drug which reduces B-lymphocytes. This study will test the safety and efficacy of rituximab in the treatment of patients with anti-MAG polyneuropathy.
| Condition | Intervention | Phase |
|---|---|---|
|
Polyneuropathy Associated With Anti-MAG IgM Gammopathy |
Drug: Rituximab |
Phase III |
| Study Type: | Interventional |
| Study Design: | Treatment, Randomized, Double-Blind, Placebo Control, Single Group Assignment, Efficacy Study |
| Official Title: | Double-Blind Randomized Trial of Rituximab Versus Placebo in Polyneuropathy Associated With Anti-MAG IgM Monoclonal Gammopathy |
| Estimated Enrollment: | 60 |
| Study Start Date: | April 2006 |
| Estimated Study Completion Date: | January 2009 |
Acting of a polyneuropathy for which there is not any treatment of reference today (see supra), a test of double-knowledge versus placebo is justified. Acting of a chronic polyneuropathy, the clinical evaluation must be led over one one year period. Acting of a sensitive polyneuropathy and the awaited benefit being the IMPROVEMENT OF the CLINICAL SIGNS, the principal criterion is a sensitive score in addition validated in chronic sensitive polyneuropathies immunodeficiency syndrome.
The patients answering the criteria of inclusion and none inclusion (see V-2) will be randomized in 2 groups: the first group will receive a perfusion IV of rituximab to the amount of 375 mg/m2 of body surface, once per week, during 4 weeks (see VII-3); the second group will receive 4 perfusions IV of placebo according to same methods'. The evaluation (see VI-1) will be carried out at the time of the randomization, then repeated in 3 months, 6 months, 9 months and 1 year.
Eligibility| Ages Eligible for Study: | 18 Years to 82 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations| Contact: Jean-Marc LEGER, MD | +33(0)-1 42 16 37 73 | jean-marc.leger@psl.aphp.fr |
| France | |
| Groupe Hospitalier Pitié-Salpétrière, Consultation de Pathologie Neuromusculaire, Bâtiment Babinski | Recruiting |
| PARIS, France, 75015 | |
| Contact: Jean-Marc LEGER, MD,PhD +33(0)-1 42 16 37 73 jean-marc.leger@psl.aphp.fr | |
| Principal Investigator: Jean-Marc LEGER, MD | |
| Principal Investigator: | Jean-Marc LEGER, MD | Assistance Publique - Hôpitaux de Paris |
More Information
| Study ID Numbers: | P040409, AOM04058 |
| Study First Received: | November 29, 2005 |
| Last Updated: | March 13, 2007 |
| ClinicalTrials.gov Identifier: | NCT00259974 History of Changes |
| Health Authority: | France: Ministry of Health |
|
Anti-MAG monoclonal gammopathy Polyneuropathy Rituximab |
|
Immunoproliferative Disorders Immune System Diseases Immunologic Factors Antineoplastic Agents Blood Protein Disorders Hematologic Diseases Rituximab Nervous System Diseases |
Physiological Effects of Drugs Polyneuropathies Paraproteinemias Pharmacologic Actions Neuromuscular Diseases Therapeutic Uses Peripheral Nervous System Diseases Antirheumatic Agents |
